Bayer Innovation Procurement Expands Use of Scientist.com’s AI-Powered Platform for Global R&D Procurement Orchestration
16.6.2025 13:55:00 CEST | Business Wire | Press release
Bayer AG Innovation Procurement and Scientist.com have signed a multi-year extension that elevates Scientist.com to Bayer’s preferred global channel for sourcing external R&D services.
A Journey from Tactical to Strategic Partnership
The alliance began in 2015, when Bayer adopted Scientist.com’s digital marketplace to streamline and control long-tail spend in preclinical research. Over the years, this relationship has deepened and expanded, reflecting Bayer’s broader shift toward externalizing more of its R&D activities as part of its innovation strategies. What started as a tactical procurement tool has now become Bayer’s preferred global channel for sourcing a wide spectrum of external R&D services.
Comprehensive R&D Outsourcing Capabilities
With the expansion, Scientist.com’s platform will support Bayer across the entire R&D value chain, including:
- Strategic preclinical supplier management, with guided buying, rate-card compliance, and performance tracking.
- Clinical development services, offering unified workflows for study execution, biomarker analysis, and central laboratory capabilities.
- Real-world evidence, data analytics, health economics, and market access solutions, providing rapid access to top-tier data partners.
- Crop science research, including specialized agriscience testing and regulatory studies.
Driving Digital Transformation and Innovation
By designating Scientist.com as its preferred sourcing channel, Bayer Innovation Procurement has created a single digital entry point for its scientists – enabling access to both strategic and niche providers, automating governance, supporting sustainability goals, and generating actionable insights from aggregated procurement data. This transformation is part of Bayer Innovation Procurement’s strategy to empower Bayer researchers and increase the flexibility and productivity of R&D activities in line with the company wide operating model Dynamic Shared Ownership. The full expansion of Crop Science Research and Clinical Development Services are expected to steadily roll out over the next 6-12 months to enable for the onboarding of Bayer’s full provider list.
Leadership Perspectives
“Scientist.com has proven its value right from the beginning, and this extension makes it the one place our scientists go for most of their external work,” said Dr. Kirstin Meyer, SVP and Head of Pre-clinical Development Research, Bayer AG. “With a single entry point we can reach strategic and niche providers alike, ensure governance, drive our sustainability goals and – critically – generate insights from the aggregated data to guide future decisions.”
“Bayer is showing how a digital procurement orchestration platform can serve as an enterprise solution that streamlines an entire research organization's sourcing processes," said Dr. Dan Kagan, President & COO, Scientist.com. “Together we’re adding new AI tools, deeper data integrations and end-to-end compliance so Bayer teams across Pharma and Crop Science can innovate faster and smarter.”
Scientist.com’s AI-enabled platform combines supplier discovery, competitive bidding, contracting, compliance checks and spend analytics in one secure environment, giving Bayer researchers a seamless path to the expertise they need while unlocking portfolio-level insights from the underlying data.
A Model for the Future of R&D
The evolution of Bayer’s partnership with Scientist.com exemplifies how leading life science organizations are moving beyond tactical procurement toward strategic, digitally enabled R&D outsourcing. This approach not only enhances operational efficiency but also positions Bayer to better leverage global expertise, accelerate innovation, and respond to changing scientific and market demands.
About Scientist.com
Scientist.com is the life-science industry’s premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world’s top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on Scientist.com to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Discover how Scientist.com accelerates science at Scientist.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616174530/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom